Pleiotropic effects of incretins
Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement in postprandial hyperglycemia) and suppress g...
Main Author: | Vishal Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2012;volume=16;issue=7;spage=47;epage=56;aulast=Gupta |
Similar Items
-
Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01) -
The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-04-01) -
Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-04-01) -
Understanding the Cardiovascular Effects of Incretin
by: Ji Sung Yoon, et al.
Published: (2011-10-01) -
Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)